Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;44(3):310-321.
doi: 10.1007/s12272-021-01315-9. Epub 2021 Feb 15.

Protein tyrosine phosphatases (PTPs) in diabetes: causes and therapeutic opportunities

Chiranjeev Sharma  1 , Youllee Kim  1 , Dohee Ahn  1 , Sang J Chung  2
Affiliations
Review

Protein tyrosine phosphatases (PTPs) in diabetes: causes and therapeutic opportunities

Chiranjeev Sharma et al. Arch Pharm Res. 2021 Mar.

Abstract

Protein tyrosine phosphatases (PTPs) have an emerging paradigm for the development of antidiabetic drugs. Herein, we provide a comprehensive overview of the relevance of PTPs to type 2 diabetes (T2D) and the therapeutic opportunities thereof, while critically evaluating the potential challenges for PTP inhibitors to be next generation antidiabetics. This review briefly discusses the structure and function of PTPs. An account of importance and relevance of PTPs in various human diseases is presented with special attention to diabetes. The PTPs relevant to T2D have been targeted by small molecule inhibitors such as natural products and synthetic compounds as well as antisense nucleic acids. This review will give better understanding of the important concepts helpful in outlining the strategies for the development of new therapeutic agents with promising antidiabetic activities.

Keywords: Antidiabetic agents; Antisense; Natural product; PTP inhibitor; Type 2 diabetes.

PubMed Disclaimer

References

    1. Alonso A, Pulido R (2016) The extended human PTPome: a growing tyrosine phosphatase family. FEBS J 283:1404–1429. https://doi.org/10.1111/febs.13600 - DOI - PubMed
    1. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T (2004) Protein tyrosine phosphatases in the human genome. Cell 117:699–711. https://doi.org/10.1016/j.cell.2004.05.018 - DOI - PubMed
    1. Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, Møller NP (2001) Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 21:7117–7136. https://doi.org/10.1128/MCB.21.21.7117-7136.2001 - DOI - PubMed - PMC
    1. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Bärnighausen T, Davies J, Vollmer S (2018) Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care 41:963–970. https://doi.org/10.2337/dc17-1962 - DOI - PubMed
    1. Brenachot X, Ramadori G, Ioris RM, Veyrat-Durebex C, Altirriba J, Aras E, Ljubicic S, Kohno D, Fabbiano S, Clement S, Goossens N, Trajkovski M, Harroch S, Negro F, Coppari R (2017) Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance. Nat Comm 8:1820. https://doi.org/10.1038/s41467-017-02074-2 - DOI

MeSH terms

LinkOut - more resources